Comparative long-term effects of interferon α and hydroxyurea on human hematopoietic progenitor cells

Experimental Hematology

Volumn 43, Issue 10, 2015, Pages 912-918.e2

  King, Katherine Y ^a   Matatall, Katie A ^a   Shen, Ching Chieh ^b   Goodell, Margaret A ^a   Swierczek, Sabina I ^c   Prchal, Josef T ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; JANUS KINASE 2; PEGINTERFERON ALPHA; ALPHA INTERFERON; JAK2 PROTEIN, HUMAN;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL COUNT; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; CELL PROLIFERATION; CELL RENEWAL; COLONY FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DETERMINATION; DRUG DOSE ESCALATION; FEMALE; GENE MUTATION; GENETIC TRANSCRIPTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; JAK2 GENE; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE NEOPLASM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ANIMAL; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; MIDDLE AGED; MOUSE; PATHOLOGY; POLYCYTHEMIA VERA; THROMBOCYTHEMIA, ESSENTIAL; TIME FACTOR;

AGED; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MICE; MIDDLE AGED; POLYCYTHEMIA VERA; THROMBOCYTHEMIA, ESSENTIAL; TIME FACTORS;

EID: 84942551412     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2015.05.013     Document Type: Article

References (28)

1. Friedman R. Clinical uses of interferons. Br J Clin Pharmacol 2008, 65:158-162.
2. Kiladjian J.J., Cassinat B., Turlure P., et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006, 108:2037-2040.
3. Hasselbalch H.C. A new era for IFN-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol 2011, 4:637-655.
4. Preudhomme C., Guilhot J., Nicolini F.E., et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010, 363:2511-2521.
5. Lu M., Zhang W., Li Y., et al. Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol 2010, 38:472-480.
6. Raefsky E.L., Platanias L.C., Zoumbos N.C., Young N.S. Studies of interferon as a regulator of hematopoietic cell proliferation. J Immunol 1985, 135:2507-2512.
7. Chawla-Sarkar M., Lindner D.J., Liu Y.F., et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003, 8:237-249.
8. Essers M.A.G., Offner S., Blanco-Bose W.E., et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009, 458:904-908.
9. Baldridge M.T., King K.Y., Boles N.C., Weksberg D.C., Goodell M.A. Quiescent haematopoietic stem cells are activated by IFN-γ in response to chronic infection. Nature 2010, 465:793-797.
10. King K.Y., Baldridge M.T., Weksberg D.C., et al. Irgm1 protects hematopoietic stem cells by negative regulation of IFN signaling. Blood 2011, 118:1525-1533.
11. Pietras E.M., Lakshminarasimhan R., Techner J.M., et al. Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons. J Exp Med 2014, 211:245-262.
12. Prchal J.T. Polycythemia vera and other primary polycythemias. Curr Opin Hematol 2005, 12:112-116.
13. James C., Ugo V., Le Couédic J., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
14. Glimm H., Oh I.H., Eaves C.J. Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S/G(2)/M transit and do not reenter G(0). Blood 2000, 96:4185-4193.
15. Gaikwad A., Nussenzveig R., Liu E., Gottshalk S., Chang K., Prchal J.T. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele. Exp Hematol 2007, 35:587-595.
16. Nussenzveig R.H., Swierczek S.I., Jelinek J., et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007, 35:32-38.
17. Rutherford M.N., Hannigan G.E., Williams B.R. Interferon-induced binding of nuclear factors to promoter elements of the 2-5A synthetase gene. EMBO J 1988, 7:751-759.
18. Wathelet M., Moutschen S., Cravador A., et al. Full-length sequence and expression of the 42 kDa 2-5A synthetase induced by human interferon. FEBS Lett 1986, 196:113-120.
19. Abkowitz J.L., Chen J.C.P. Studies of c-Mpl function distinguish the replication of hematopoietic stem cells from the expansion of differentiating clones. Blood 2007, 109:5186-5190.
20. Zhang Y., Stehling-Sun S., Lezon-Geyda K., et al. PR-domain-containing Mds1-Evi1 is critical for long-term hematopoietic stem cell function. Blood 2011, 118:3853-3861.
21. Kimura S., Roberts A.W., Metcalf D., Alexander W.S. Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci U S A 1998, 95:1195-1200.
22. Chambers S.M., Shaw C.A., Gatza C., Fisk C.J., Donehower L., Goodell M.A. Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation. PLoS Biol 2007, 5:e201.
23. Matatall K.A., Shen C.C., Challen G.A., King K.Y. Type II Interferon promotes differentiation of myeloid-biased hematopoietic stem cells. Stem Cells 2014, 32:3023-3030.
24. Mirantes C., Passegué E., Pietras E.M. Pro-inflammatory cytokines: emerging players regulating HSC function in normal and diseased hematopoiesis. Exp Cell Res 2014, 329:248-254.
25. Beerman I., Seita J., Inlay M.A., Weissman I.L., Rossi D.J. Quiescent hematopoietic stem cells accumulate DNA damage during aging that is repaired upon entry into cell cycle. Cell Stem Cell 2014, 15:37-50.
26. Dykstra B., Olthof S., Schreuder J., Ritsema M., de Haan G. Clonal analysis reveals multiple functional defects of aged murine hematopoietic stem cells. J Exp Med 2011, 208:2691-2703.
27. Mullally A., Bruedigam C., Poveromo L., et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood 2013, 121:3692-3702.
28. Hasan S., Lacout C., Marty C., et al. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα. Blood 2013, 122:1464-1477.